| abstract |
A pyrazinoisoquinoline or naphthalene compound of the formula (1), wherein R1 and R2 are the same or different and each is a group selected from a hydroxyl group and a lower alkoxy group, the A0 ring is a group of the formulas (2 ) or (3), ring A is (a) a substituted or unsubstituted benzene ring or a substituted or unsubstituted aromatic heterocyclic ring, when ring A0 is a group of the formula (2) or (b) a group of the formula (4) wherein n is an integer from 1 to 6, when the ring A0 is a group of the formula (3), R3 is (a) an atom of H, a group of the formula - (CH2) m-R31 or a group of the formula -CO-R32, when the A ring is a substituted or unsubstituted aromatic benzyl ring or (b) a group of the formula - (CH2) m-R31 or a group of the formula -CO-R32, when ring A is an unsubstituted benzene ring; R31 is an H atom, an aryl group, a hydroxyl group, an amino group, a carboxyl group, a lower alkoxycarbonyl group or a lower alkylthio group, R32 is an aryl group, a lower alkyl group, a lower hydroxyalkyl group or a lower aminoalkyl group; m is an integer from 1 to 6; Q is a simple bond linked to ring A; and Ra and Rb are the same or different and each is a group selected from an H atom, an acyl group, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising as active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition is used for prophylaxis or treatment of a disease associated with PDE4, such as inflammatory or allergic disease. |